CSIMarket Company Name, Ticker, Competitors, else..


Repligen Corp  (NASDAQ: RGEN)
Other Ticker:  
 

Repligen Corp

RGEN's Fundamental analysis



Looking into Repligen growth rates, revenue grew by 10.44 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 677

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 11.44 %

Repligen's net income grew by 76.88 % in first quarter of 2025 year on year, above company average,

• More on RGEN's Growth


Repligen
realized a net loss in trailing twelve months.

Repligen realized cash reduction of $ -1.47 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 11.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.


• More on RGEN's Valuation
 
 Total Debt (Millions $) 530
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 361,349
 Net Income/Employee (TTM) $ -12,767
 Receivable Turnover (TTM) 4.87
 Tangible Book Value (Per Share $) 8.73

Repligen
realized net loss in trailing twelve months.

Repligen realized cash outflow of $ -1.47per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 11.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.

Repligen Price to Book Ratio is at 3.6 higher than Industry Avg. of -87993.38, and higher than S&P 500 Avg. of 0.01

• More on RGEN's Valuation

•  Market Capitalization (Millions $) 7,155
•  Shares Outstanding (Millions) 57
•  Employees 1,800
•  Revenues (TTM) (Millions $) 650
•  Net Income (TTM) (Millions $) -23
•  Cash Flow (TTM) (Millions $) -83
•  Capital Exp. (TTM) (Millions $) -29
•  Total Debt (Millions $) 530
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 361,349
•  Net Income/Employee(TTM) $ -12,767
•  Receivable Turnover Ratio (TTM) 4.87
•  Tangible Book Value (Per Share $) 8.73

•  Market Capitalization (Millions $) 7,155
•  Shares Outstanding (Millions) 57
•  Employees 1,800
•  Revenues (TTM) (Millions $) 650
•  Net Income (TTM) (Millions $) -23
•  Cash Flow (TTM) (Millions $) -83
•  Capital Exp. (TTM) (Millions $) -29


    RGEN's Profitability Comparisons
Repligen achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 3.89 %.

Repligen net profit margin of 3.45 % is currently ranking no. 16 in Biotechnology & Pharmaceuticals industry, ranking no. 134 in Healthcare sector and number 1500 in S&P 500.


Profitability by Segment
segments 3.45 %
Total 3.45 %



  Ratio
•   Capital Ratio (MRQ) 7.54
•  Total Debt to Equity (MRQ) 0.27
•  Tangible Leverage Ratio (MRQ) 1.72
•  Asset Turnover Ratio (TTM) 0.24
•  Inventory Turnover Ratio (TTM) 2.16



Repligen achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 3.89 %.

Repligen net profit margin of 3.45 % is currently ranking no. 16 in Biotechnology & Pharmaceuticals industry, ranking no. 134 in Healthcare sector and number 1500 in S&P 500.

• More on RGEN's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com